Arvinas, Inc. is a biopharmaceutical company that develops and commercializes therapies to eliminate disease-causing proteins. The company's lead product candidates are Bavdegalutamide, ARV-471 and ARV-766, which are PROTAC protein degraders designed for the treatment of men with metastatic castration-resistant prostate cancer, patients with breast cancer, and for the treatment of mCRPC. The company has partnerships with renowned pharmaceutical companies, including Pfizer, Roche, Genentech and Bayer.